DarioHealth Appoints Healthcare Technology Entrepreneur and Venture Capital Partner Yoav Shaked as Chairman of the Board
Jul 9, 2018
CAESAREA, Israel, July 9, 2018 /PRNewswire/ --– DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today Yoav Shaked has joined the Company as Chairman of the Board. The Company's Chief Executive Officer, Erez Raphael shall continue serving on the board of directors and as CEO.
Mr. Shaked is a partner at Sequoia Capital, a world leading venture capital firm. Over the past 20 years he has built and sold companies in the medical technology space. He founded and served as Chief Executive Officer of Y-Med through its sale to C.R. Bard. Mr. Shaked has served at executive positions at XTechnologies a cardiovascular device developer until it was sold to Guidant and as a Director of Research at ThermopeutiX, a developer of innovative products for strokes and peripheral artery disease. He serves on the board of directors of several biotechnology companies including Endospan, Vibrant Gastro, B-Lite (G&G Biotechnology) and Orasis Pharmaceuticals, where he is Chairman of the Board.
"We are honored to welcome Yoav Shaked to our board as Chairman and we believe the move shows his strong belief in DarioHealth's vision to transform the management of chronic disease through digital health systems. His wealth of experience recognizing promising healthcare technologies and building profitable companies around them will be an asset that helps drive DarioHealth into a market leadership position in digital healthcare technologies," stated DarioHealth CEO Erez Raphael.
DarioHealth Chairman Mr. Shaked commented, "Digital health technologies have the potential to revolutionize healthcare. Like most other digital platforms, user engagement is key. When a digital health solution becomes a patient's daily companion and assistant that is when it is truly differentiated and becomes an essential presence in the life of the patient. DarioHealth has achieved this level of engagement with tens of thousands of users today and I believe they can be the dominant player in the management of chronic disease through digital health platforms."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that its new chairman's wealth of experience will be an asset that helps drive DarioHealth into a market leadership position in digital healthcare technologies, or that it can be the dominant player in the management of chronic disease through digital health platforms, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
DarioHealth Investor Relations Contact:
SOURCE DarioHealth Corp.